Boehringer Ingelheim Recalls Oxcarbazepine Oral Suspension Due to Resuspension Issues
Boehringer Ingelheim is recalling 10,267 bottles of Oxcarbazepine Oral Suspension because the product failed to meet resuspendability requirements.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, but the source text does not report any illnesses, injuries, or hospitalizations. The hazard is a quality defect (resuspendability) rather than a high-risk pathogen or structural defect, fitting the criteria for a moderate severity score.
Plain-English summary
Boehringer Ingelheim Roxane Inc. is recalling 10,267 bottles of Oxcarbazepine Oral Suspension, 300 mg/5 mL, 250 mL bottles. The affected product is identified by Lot # 161304B with an expiration date of OCT 2013. The recall is classified as Class II by the U.S. Food and Drug Administration.
The recall was initiated because the recalled lot did not meet resuspendability requirements. This means the medication may not mix properly when shaken, which could affect the consistency of the dose. The product was distributed nationwide.
Consumers who have this specific lot of Oxcarbazepine Oral Suspension should stop using it and contact their healthcare provider or pharmacist for guidance on obtaining a replacement or alternative treatment. The recall number is D-002-2014.
The recalled product
- Product
- Oxcarbazepine Oral Suspension, 300 mg/5 mL, 250 mL bottle, Rx only, Boehringer Ingelheim, Roxane Laboratories, Inc. Columbus, Ohio 43216, NDC 0054-0199-59
- Manufacturer
- Boehringer Ingelheim Roxane Inc
- Category
- Drug — Anticonvulsant
- Affected units
- 10,267
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # 161304B
- Exp. OCT 2013
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Boehringer Ingelheim Roxane Inc
See all →- ModerateBoehringer Ingelheim Roxane Recalls Furosemide Tablets Due to Manufacturing Error
FDA (Drugs) · 2015-10-21
- ModerateBoehringer Ingelheim Roxane Recalls Furosemide Tablets Due to CGMP Deviations
FDA (Drugs) · 2015-10-21
- ModerateBoehringer Ingelheim Recalls Defective Combivent Respimat Inhalers
FDA (Drugs) · 2015-08-05
- ModerateBoehringer Ingelheim Roxane Recalls Subpotent Acarbose Tablets
FDA (Drugs) · 2015-06-03
- LowOxycodone Hydrochloride Oral Solution Recalled for Stability Failure
FDA (Drugs) · 2014-08-06
Same hazard · quality defect
See all →- ModerateDicyclomine Hydrochloride Capsules Recalled for Empty Capsules
FDA (Drugs) · 2026-08-12
- ModerateMethohexital Sodium for Injection Recalled for Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-15
- ModerateMedline Lidocaine HCL Injection Ampules Recalled for Quality Issues
FDA (Devices) · 2026-07-08
- ModerateMedline Convenience Kits Block Tray recalled due to quality defects
FDA (Devices) · 2026-07-08
- ModerateMedline Ophthalmic Pack with Lidocaine Injection Kits Recalled
FDA (Devices) · 2026-07-08